Advertisement

Topics

Semafore Pharmaceuticals Inc. Company Profile

14:44 EDT 27th August 2016 | BioPortfolio

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.


News Articles [1257 Associated News Articles listed on BioPortfolio]

Jazz Pharmaceuticals Acquires Celator for $1.5B

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator ...

M&As this week: Scintilla Pharmaceuticals, Lonza Group Ltd, Piramal Enterprises Limited

Scintilla Pharmaceuticals has entered a binding term sheet to acquire Semnur Pharmaceuticals for a purchase consideration of up to $200m.

Jazz Pharmaceuticals to Acquire Celator

NewsJazz Pharmaceuticals and Celator Pharmaceuticals announce agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share.

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To ...

1Included secondary AML and de novo AML with a karyotype characteristic of myelodysplastic syndrome (MDS) 2 U.S. FDA Breakthrough Therapy designat...

Novartis splits pharmaceuticals division into two business units

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology, reporting ...

Scintilla to Acquire SCILEX Pharmaceuticals

NewsScintilla Pharmaceuticals to acquire SCILEX Pharmaceuticals to add a late-stage asset to bolster its pain management business.

M&As this week: Savara Pharma, Xiangxue Pharmaceuticals

Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.

Ampio Pharma spins off Vyrix Pharmaceuticals

Ampio Pharmaceuticals Inc. (drugs for inflammatory conditions) spun off its sexual dysfunction business into Vyrix Pharmaceuticals Inc.

Drugs and Medications [0 Results]

None

PubMed Articles [146 Associated PubMed Articles listed on BioPortfolio]

Biotransformation of pharmaceuticals by ammonia oxidizing bacteria in wastewater treatment processes.

Pharmaceutical residues could potentially pose detrimental effects on aquatic ecosystems and human health, with wastewater treatment being one of the major pathways for pharmaceuticals to enter into t...

Removal of pharmaceuticals from secondary effluents by an electro-peroxone process.

This study compared the removal of pharmaceuticals from secondary effluents of wastewater treatment plants (WWTPs) by conventional ozonation and the electro-peroxone (E-peroxone) process, which involv...

Ranking Prescribed Pharmaceuticals in Terms of Environmental Risk: Inclusion of Hospital Data and the Importance of Regular Review.

A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have bee...

Announcing the 2016 Pharmaceuticals Travel Award for Young Investigators.

For the first time in its short history, our journal is able, this year, to support a young researcher in the field of medicinal chemistry by offering a travel grant of 800 CHF.[...].

Uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin and propranolol, in Daphnia magna.

The objective of the present study was to investigate the uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin (ROX) and propranolol (PRP), in Daphnia magna via aqueous expos...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.

This study evaluates the frequency of occurrence, severity, and response to treatment by a chemical agent, notably the dimerizer AP1903 (Bellicum Pharmaceuticals compagny), in the case of ...

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elide...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

TOL-463 Phase 2 Study

This is a Phase II randomized single blind (investigator-blinded) safety and efficacy study in approximately 90 adult females 18-50 years of age (to achieve 80 evaluable participants) at t...

Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL)

This phase III clinical study will be conducted in Brazilian research sites. It will be included in the study 314 participants diagnosed with primary knee OA according to the classificatio...

Companies [3 Associated Companies listed on BioPortfolio]

Semafore Pharmaceuticals Inc.

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple ...

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a private, clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibitors targe...

Semafore Pharmaceuticals, Inc.

Founded in 2000, Semafore Pharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule signal transduction inhibito...

More Information about "Semafore Pharmaceuticals Inc." on BioPortfolio

We have published hundreds of Semafore Pharmaceuticals Inc. news stories on BioPortfolio along with dozens of Semafore Pharmaceuticals Inc. Clinical Trials and PubMed Articles about Semafore Pharmaceuticals Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Semafore Pharmaceuticals Inc. Companies in our database. You can also find out about relevant Semafore Pharmaceuticals Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record